

# R Stephanie Huang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7114865/r-stephanie-huang-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55  
papers

2,223  
citations

22  
h-index

47  
g-index

60  
ext. papers

3,458  
ext. citations

11.9  
avg, IF

5.34  
L-index

#	Paper	IF	Citations
55	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer.. <i>Science China Life Sciences</i> , <b>2022</b> , 1	8.5	1
54	Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 6377	17.4	0
53	A Long Noncoding RNA, GAS5 Can Be a Biomarker for Docetaxel Response in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 675215	5.3	0
52	HGG-12. HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE. <i>Neuro-Oncology</i> , <b>2021</b> , 23, ii19-ii20	1	78
51	Oncogene or tumor suppressor? Long noncoding RNAs role in patient's prognosis varies depending on disease type. <i>Translational Research</i> , <b>2021</b> , 230, 98-110	11	4
50	Facilitating Drug Discovery in Breast Cancer by Virtually Screening Patients Using In Vitro Drug Response Modeling. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
49	oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. <i>Briefings in Bioinformatics</i> , <b>2021</b> , 22,	13.4	16
48	TMOD-07. HUMAN DIFFUSE MIDLINE GLIOMA AVATARS AS A PLATFORM TO SEARCH FOR NOVEL THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , <b>2020</b> , 22, ii229-ii229	1	
47	Emerging role of long non-coding RNAs in cancer precision medicine. <i>Molecular and Cellular Oncology</i> , <b>2020</b> , 7, 1684130	1.2	2
46	iMIRAGE: an R package to impute microRNA expression using protein-coding genes. <i>Bioinformatics</i> , <b>2020</b> , 36, 2608-2610	7.2	1
45	Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action. <i>Nature Communications</i> , <b>2020</b> , 11, 5848	17.4	14
44	Long non-coding RNA transcriptome of uncharacterized samples can be accurately imputed using protein-coding genes. <i>Briefings in Bioinformatics</i> , <b>2020</b> , 21, 637-648	13.4	3
43	Discovering long noncoding RNA predictors of anticancer drug sensitivity beyond protein-coding genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 22020-22029 <sup>16</sup>	11.5	16
42	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1436	5.6	6
41	Cancer expression quantitative trait loci (eQTLs) can be determined from heterogeneous tumor gene expression data by modeling variation in tumor purity. <i>Genome Biology</i> , <b>2018</b> , 19, 130	18.3	12
40	More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 191, 178-189	13.9	12
39	The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2017</b> , 15, 82-93	6.5	32

38	Exploring the Link between the Germline and Somatic Genome in Cancer. <i>Cancer Discovery</i> , <b>2017</b> , 7, 354-355	2.4	7
37	Institutional Profile: Pharmacogenomic research in R Stephanie Huang Laboratory. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 519-522	2.6	
36	Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. <i>Molecular Diagnosis and Therapy</i> , <b>2017</b> , 21, 621-631	4.5	8
35	Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies. <i>Genome Research</i> , <b>2017</b> , 27, 1743-1751	9.7	65
34	Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile. <i>Oncotarget</i> , <b>2017</b> , 8, 115102-115113	3.3	1
33	High Expression of miR-532-5p, a Tumor Suppressor, Leads to Better Prognosis in Ovarian Cancer Both In Vivo and In Vitro. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1123-31	6.1	38
32	Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 38359-38366	3.3	3
31	Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. <i>PLoS ONE</i> , <b>2016</b> , 11, e0168284	3.7	63
30	Lymphoblastoid Cell Lines as a Tool to Study Inter-Individual Differences in the Response to Glucose. <i>PLoS ONE</i> , <b>2016</b> , 11, e0160504	3.7	5
29	Cancer biomarker discovery is improved by accounting for variability in general levels of drug sensitivity in pre-clinical models. <i>Genome Biology</i> , <b>2016</b> , 17, 190	18.3	27
28	Consistency in large pharmacogenomic studies. <i>Nature</i> , <b>2016</b> , 540, E1-E2	50.4	35
27	MicroRNA biogenesis and cellular proliferation. <i>Translational Research</i> , <b>2015</b> , 166, 145-51	11	16
26	Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond. <i>Chinese Journal of Cancer</i> , <b>2015</b> , 34, 149-60		18
25	Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	13
24	The impact of the Cancer Genome Atlas on lung cancer. <i>Translational Research</i> , <b>2015</b> , 166, 568-85	11	56
23	The impact of microRNA expression on cellular proliferation. <i>Human Genetics</i> , <b>2014</b> , 133, 931-8	6.3	29
22	Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. <i>Genome Biology</i> , <b>2014</b> , 15, R47	18.3	297
21	Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. <i>BMC Genomics</i> , <b>2014</b> , 15, 292	4.5	19

20	Integrative "omic" analysis for tamoxifen sensitivity through cell based models. <i>PLoS ONE</i> , <b>2014</b> , 9, e93439	3.7	297
19	pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. <i>PLoS ONE</i> , <b>2014</b> , 9, e107468	3.7	297
18	Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line. <i>PLoS ONE</i> , <b>2014</b> , 9, e115003	3.7	7
17	Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. <i>Genomics, Proteomics and Bioinformatics</i> , <b>2014</b> , 12, 198-209	6.5	42
16	Genetic variation is the major determinant of individual differences in leukocyte endothelial adhesion. <i>PLoS ONE</i> , <b>2014</b> , 9, e87883	3.7	4
15	Translating pharmacogenomics discoveries into the clinic: an implementation framework. <i>Genome Medicine</i> , <b>2013</b> , 5, 94	14.4	6
14	Pharmacogenomics discovery and implementation in genome-wide association studies era. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , <b>2013</b> , 5, 1-9	6.6	22
13	Circulating microRNAs as biomarkers for inflammatory diseases. <i>MicroRNA (Sharjah, United Arab Emirates)</i> , <b>2013</b> , 2, 63-71	2.9	62
12	Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5490-500	12.9	55
11	Population differences in microRNA expression and biological implications. <i>RNA Biology</i> , <b>2011</b> , 8, 692-704	11.8	115
10	Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 471-4	2.6	11
9	Gene Set Enrichment Analyses Revealed Differences in Gene Expression Patterns between Males and Females. <i>In Silico Biology</i> , <b>2009</b> , 9, 55-63	2	20
8	Population-specific GSTM1 copy number variation. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 366-72	5.6	33
7	Pharmacogenetics and pharmacogenomics of anticancer agents. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2009</b> , 59, 42-55	220.7	95
6	Genetic variants contributing to daunorubicin-induced cytotoxicity. <i>Cancer Research</i> , <b>2008</b> , 68, 3161-8	10.1	62
5	Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3038-46	6.1	57
4	Identification of genetic variants and gene expression relationships associated with pharmacogenes in humans. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 545-9	1.9	19
3	A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 9758-63	11.5	179

- |   |                                                                                                                                                                                          |     |     |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----|
| 2 | Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 31-6                                             | 6.1 | 74  |
| 1 | Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genome-wide approach. <i>American Journal of Human Genetics</i> , <b>2007</b> , 81, 427-37 | 11  | 159 |